Compare Taskus Inc (TASK) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Tempus AI — how do they compare? Taskus Inc trades at $8.15 (market cap $723.41M), while Tempus AI trades at $70.9 (market cap $12.58B). The key difference: Tempus AI is far larger — about 17.4× Taskus Inc's market cap, and Tempus AI is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 34 Days and Tempus AI for 23 Days on average.
| TASK | TEM | |
|---|---|---|
Market Cap | $723.41M | $12.58B |
Volume | 201,303 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $14.69 | $99.28 |
52-Week Low | $4.57 | $41.55 |
Typical Hold Time | 34 Days | 23 Days |
Enterprise Value | $1.09B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs trades at $8.08, up 2.41% today, with a bearish technical signal but strong fundamentals including a low P/E of 6.8 and robust ROE of 25.43%. Recent Q2 2026 earnings beat estimates with $0.33 EPS versus $0.29 expected, driven by 5% revenue growth to $308.9 million. The company shows consistent cash flow generation with $137 million from operations in 2025.
The stock appears undervalued with analyst consensus target of $9.33 offering 15% upside potential. Key risks include margin compression from higher labor costs and dependence on AI segment growth. Institutional ownership increased with Dimensional Fund Advisors raising its stake by 12.8% in Q1 2026.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
